T1	Participants 50 148	advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
T2	Participants 255 368	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
T3	Participants 1140 1292	More S/CC patients enrolled on trials with advanced stage (III-IV) disease (as opposed to recurrent disease) compared to E patients (45% vs. 24%, p<0.05
